What is HC Wainwright’s Forecast for InflaRx Q1 Earnings?

InflaRx N.V. (NASDAQ:IFRX) – HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of InflaRx in a research report issued to clients and investors on Thursday, March 19th. HC Wainwright analyst M. Keller anticipates that the company will earn ($0.14) per share for the quarter. HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for InflaRx’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for InflaRx’s Q2 2026 earnings at ($0.13) EPS.

Other research analysts have also issued research reports about the company. Leerink Partners reaffirmed a “market perform” rating and set a $2.00 price target (down from $5.00) on shares of InflaRx in a research report on Wednesday, December 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a report on Monday, December 29th. Finally, Raymond James Financial restated an “outperform” rating on shares of InflaRx in a report on Wednesday, December 31st. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, InflaRx presently has a consensus rating of “Moderate Buy” and an average target price of $7.50.

InflaRx Trading Up 3.4%

Shares of IFRX stock opened at $0.91 on Friday. The firm’s fifty day moving average price is $0.93 and its two-hundred day moving average price is $1.15. InflaRx has a 1 year low of $0.71 and a 1 year high of $1.94. The firm has a market capitalization of $61.06 million, a P/E ratio of -1.34 and a beta of 1.48.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings data on Thursday, March 19th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The firm had revenue of ($0.04) million for the quarter, compared to analyst estimates of $0.03 million.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in IFRX. Suvretta Capital Management LLC lifted its holdings in InflaRx by 22.4% during the 4th quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after purchasing an additional 1,450,000 shares during the last quarter. 683 Capital Management LLC raised its position in shares of InflaRx by 47.3% in the fourth quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company’s stock valued at $3,348,000 after purchasing an additional 1,065,000 shares during the period. Bank of America Corp DE acquired a new stake in shares of InflaRx during the 3rd quarter worth about $3,316,000. Eversept Partners LP lifted its stake in shares of InflaRx by 1.5% during the 4th quarter. Eversept Partners LP now owns 1,757,312 shares of the company’s stock worth $1,775,000 after buying an additional 26,677 shares during the last quarter. Finally, Woodline Partners LP bought a new stake in shares of InflaRx during the 1st quarter worth about $766,000. 42.39% of the stock is owned by institutional investors and hedge funds.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.